Nectar Lifesciences Intrinsic Value
Nectar Lifesciences intrinsic value. Nectar Lifesciences (NECLIFE) median intrinsic value is ₹19.62 from 8 valuation models (range ₹4–₹29), vs current price ₹9.81 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Analyse NECLIFE FII DII holdings to track promoter, FII and institutional holdings.
NECLIFE Valuation Methods Summary — DCF, Graham Number & P/E
Nectar Lifesciences intrinsic value across 8 models vs current price ₹9.81 — upside/downside and value range per method. For current market price and key ratios, visit Nectar Lifesciences share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹12.32 | ₹9.86 - ₹14.78 | +25.6% | EPS: ₹0.56, Sector P/E: 22x |
| Book Value Method | asset | ₹24.53 | ₹22.08 - ₹26.98 | +150.1% | Book Value/Share: ₹306.32, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹19.62 | ₹17.66 - ₹21.58 | +100.0% | Revenue/Share: ₹29.47, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹19.62 | ₹17.66 - ₹21.58 | +100.0% | EBITDA: ₹28.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹24.53 | ₹19.62 - ₹29.44 | +150.1% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹3.58 | ₹3.22 - ₹3.94 | -63.5% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹8.65 | ₹7.79 - ₹9.52 | -11.8% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹29.43 | ₹26.49 - ₹32.37 | +200.0% | EPS: ₹0.56, BVPS: ₹306.32 |
NECLIFE Intrinsic Value vs Market Price — All Valuation Models
Nectar Lifesciences fair value range ₹4–₹29 vs current market price ₹9.81 across 8 valuation models. Browse NECLIFE income statement for revenue, profit, balance sheet and cash flow data.
NECLIFE Intrinsic Value Analysis — Undervalued or Overvalued?
Nectar Lifesciences median intrinsic value ₹19.62, current price ₹9.81 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of NECLIFE?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Nectar Lifesciences (NECLIFE) is ₹19.62 (median value). With the current market price of ₹9.81, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹3.58 to ₹29.43, indicating ₹3.58 - ₹29.43.
Is NECLIFE undervalued or overvalued?
Based on our multi-method analysis, Nectar Lifesciences (NECLIFE) appears to be trading below calculated value by approximately 100.0%.
NECLIFE Financial Health — Key Ratios vs Industry Benchmarks
Nectar Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 2.1% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -75200.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.09x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
NECLIFE Cash Flow Quality — Operating & Free Cash Flow
Nectar Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹-349 Cr | ₹-349 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹169 Cr | ₹148 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹225 Cr | ₹217 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹134 Cr | ₹134 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹95 Cr | ₹95 Cr | Positive Free Cash Flow | 8/10 |